Login / Signup

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Carlos Gomez-RocaPhilippe CassierDmitriy ZamarinJean-Pascal H MachielsJose Luis Perez GraciaF Stephen HodiAlvaro TausMaria Martinez GarciaValentina BoniJoseph P EderNavid HafezRyan J SullivanDavid McdermottStephane ChampiatSandrine AspeslaghCatherine TerretAnna-Maria JeggWolfgang JacobMichael A CannarileCarola RiesKonstanty KorskiFrancesca MichielinRandolph ChristenGalina BabitzkiCarl WatsonGeorgina Meneses-LorenteMartin WeisserDominik RüttingerJean-Pierre DelordAurélien Marabelle
Published in: Journal for immunotherapy of cancer (2022)
Emactuzumab in combination with atezolizumab demonstrated a manageable safety profile with increased fatigue and skin rash over usual atezolizumab monotherapy. A considerable ORR was particularly seen in ICB-experienced NSCLC patients. Increase ofCD8 +TILs under therapy appeared to be associated with persistence of a TAM subpopulation.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • small cell lung cancer
  • prognostic factors
  • peritoneal dialysis
  • clinical trial
  • bone marrow
  • cell therapy
  • tyrosine kinase
  • epidermal growth factor receptor